SU-E-T-12: A Comparative Dosimetric Study of Pre and Post Prostate Iodine-125 Permanent Seed Implants

2015 ◽  
Vol 42 (6Part11) ◽  
pp. 3333-3333
Author(s):  
X Liu ◽  
J Rahimian ◽  
B Goy ◽  
H Cosmatos ◽  
Y Qian
Keyword(s):  
Dosimetric Study ◽  
Iodine 125

SU-E-T-388: Dosimetric Study of a New-Generation Iodine-125 Source in Polymer: Dosimetric Impact of Fluorescence X-Rays

2011 ◽  
Vol 38 (6Part16) ◽  
pp. 3577-3577
Author(s):  
F Abboud ◽  
M Hollows ◽  
P Scalliet ◽  
S Vynckier
Keyword(s):  
X Rays ◽  
Dosimetric Study ◽  
Iodine 125 ◽  
New Generation

Dosimetic quality and evolution of edema after prostate brachytherapy for small prostates: Implications for the use of newer isotopes.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 232-232
Author(s):  
Konstantin Kovtun ◽  
Luciant D. Wolfsberger ◽  
Thomas Niedermayr ◽  
Emily Neubauer ◽  
Yonina R. Murciano-Goroff ◽  
...  
Keyword(s):  
Hot Spots ◽  
Transrectal Ultrasound ◽  
Prostate Brachytherapy ◽  
Short Term ◽  
Mri Scans ◽  
Operative Planning ◽  
Dosimetric Study ◽  
Prescription Dose ◽  
Iodine 125 ◽  
Ct And Mri

232 Background: Prostate brachytherapy is often avoided in men with small prostate volumes (PV) due to concerns about suboptimal dosimetry. We characterized prostate swelling and dosimetry in patients with small PVs compared with large PVs. Methods: We studied twenty-five patients with PV <25 cc (range 15.1-24.8) and sixty-five patients with PV >=25 cc (range 25.0-66.2) who underwent brachytherapy. Gland size was based on the contoured volume on a 3D transrectal ultrasound before the procedure. Ultrasound-guided brachytherapy was performed under intra-operative planning with loose Iodine-125 seeds to a prescription dose of 145 Gy. Patients underwent CT and MRI scans on post-implant Days 1 and 30 for dosimetric study. MRI was used to contour the prostate and then fused with the CT for dosimetry. Results: Small PVs had greater Day 1 post-implant swelling than patients with large PVs (32.5% increase in volume vs. 23.7%, p=0.04) but Day 30 swelling was minimal and not significantly different (4.4% increase in volume vs. 1.6%, p=0.44) for small and large PVs respectively. Small PVs had greater seed and needle density at implant (p<0.001). Small PV patients had larger Day 1 hot spots in the prostate at (V150 = 59.6% vs. 53.0, p=0 .022) which resolved by Day 30 (V150 = 70.9% vs. 67.1, p=0.20). Rectal and urethral doses were nearly identical by Day 30 (Small PV RV100 = 0.32 cc, Large PV RV100 = 0.33 cc, p=0.99; small PV UV150 = 0.20, large PV UV150 = 0.20, p=0.91). Day 1 swelling created cold areas (rate D90>140 Gy = 88.0% and 90.6% for the small and large PV groups respectively, p=0.71), but day 30 dosimetry was excellent (rate D90>140 Gy = 100% for both groups). Conclusions: While smaller prostates have more immediate post-operative swelling, good Day 30 dosimetry can be achieved in small prostates, which makes them excellent candidates for treatment with I-125 seeds (t½ = 60 days). Due to the increased short-term swelling, small prostates may be suboptimal candidates for implants done with shorter half-life sources such as cesium-131 (t½ = 9.7 days), where the majority of the dose may be delivered to an edematous gland.

DOSIMETRIC STUDY OF A NEW-GENERATION IODINE-125 SOURCE IN BIOCOMPATIBLE POLYMER

2009 ◽  
Vol 92 ◽  
pp. S77
Author(s):  
S. Vynckier ◽  
F. Abboud ◽  
M. Hollows ◽  
P. Scalliet
Keyword(s):  
Biocompatible Polymer ◽  
Dosimetric Study ◽  
Iodine 125 ◽  
New Generation

Vampire Bat Salivary Plasminogen Activator Promotes Robust Lysis of Plasma Clots in a Plasma Milieu Without Causing Fluid Phase Plasminogen Activation

1992 ◽  
Vol 68 (02) ◽  
pp. 165-169 ◽  
Author(s):  
Timothy R Hare ◽  
Stephen J Gardell
Keyword(s):  
Plasminogen Activator ◽  
Plasma Levels ◽  
Fluid Phase ◽  
Immunoblot Analysis ◽  
Tissue Type ◽  
Clot Lysis ◽  
Plasma Clot ◽  
Type Plasminogen Activator ◽  
Iodine 125 ◽  
Vampire Bat

SummaryVampire bat salivary plasminogen activator (BatPA), human tissue-type plasminogen activator (tPA) or streptokinase (SK) were incubated in human citrated plasma containing a plasma clot that was radiolabelled with iodine-125 fibrin(ogen). Complete clot dissolution by BatPA (30 nM) was associated with slight activation of “fluid phase” plasminogen; the plasma levels of functional fibrinogen and α2-antiplasmin decreased by only 8 and 19%, respectively. Addition of SK (3,600 IU/ml) to the clot-containing plasma caused complete clot lysis and massive activation of the “fluid phase” plasminogen, leading to >60 and 96% decreases of the functional levels of fibrinogen and α2-antiplasmin, respectively. Incubation of tPA (30 nM) in clot-containing plasma caused complete clot lysis as well as substantial activation of “fluid phase” plasminogen; the plasma levels of functional fibrinogen and α2-antiplasmin decreased by 45 and 79%, respectively. The profound degradation of fibrinogen in the SK and tPA but not BatPA-containing samples was confirmed by immunoblot analysis. Additional experiments showed that the presence of soluble clot lysate in plasma containing tPA enhanced the extent of fibrinogen degradation from 25% to >60%; the addition of soluble clot lysate to the plasma containing BatPA did not prompt further fibrinogen degradation. Finally, studies using exogenous α2-antiplasmin suggested that plasmin generated via tPA-mediated activation of “fluid phase” plasminogen does not play an important role in clot dissolution.

COMPARATIVE DOSIMETRIC STUDY IN CHEST COMPUTED TOMOGRAPHY USING PHANTOMS

2019 ◽  
Vol 7 (1A) ◽  
Author(s):  
Wadia Aburjaile ◽  
Mauricio Gomez ◽  
Arnaldo Prata Mourão
Keyword(s):  
Computed Tomography ◽  
Chest Computed Tomography ◽  
Dosimetric Study

Experimental Research on a Novel Iodine-125 Seed Strand Connected Using Magnesium Alloy AZ31

2014 ◽  
Vol 9 (2) ◽  
pp. 249-257
Author(s):  
Chuanxing Li ◽  
Yanling Zhang ◽  
Dong Chen ◽  
Guangfeng Duan ◽  
Zhenyin Liu ◽  
...  
Keyword(s):  
Magnesium Alloy ◽  
Experimental Research ◽  
Alloy Az31 ◽  
Magnesium Alloy Az31 ◽  
Iodine 125

scholarly journals Synthesis and Characterization of a Specific Iodine‐125‐Labeled TRPC5 Radioligand

ChemMedChem ◽  
2020 ◽  
Vol 15 (19) ◽  
pp. 1854-1860
Author(s):  
Yanbo Yu ◽  
Qianwa Liang ◽  
Lixia Du ◽  
Hao Jiang ◽  
Jiwei Gu ◽  
...  
Keyword(s):  
Synthesis And Characterization ◽  
Iodine 125

scholarly journals Radiation necrosis after a combination of external beam radiotherapy and iodine-125 brachytherapy in gliomas

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Indrawati Hadi ◽  
Daniel Reitz ◽  
Raphael Bodensohn ◽  
Olarn Roengvoraphoj ◽  
Stefanie Lietke ◽  
...  
Keyword(s):  
Risk Factors ◽  
Radiation Necrosis ◽  
Irradiation Time ◽  
External Beam Radiotherapy ◽  
High Grade Glioma ◽  
Metabolic Imaging ◽  
Time Interval ◽  
Low Grade ◽  
External Beam ◽  
Iodine 125

Abstract Purpose Frequency and risk profile of radiation necrosis (RN) in patients with glioma undergoing either upfront stereotactic brachytherapy (SBT) and additional salvage external beam radiotherapy (EBRT) after tumor recurrence or vice versa remains unknown. Methods Patients with glioma treated with low-activity temporary iodine-125 SBT at the University of Munich between 1999 and 2016 who had either additional upfront or salvage EBRT were included. Biologically effective doses (BED) were calculated. RN was diagnosed using stereotactic biopsy and/or metabolic imaging. The rate of RN was estimated with the Kaplan Meier method. Risk factors were obtained from logistic regression models. Results Eighty-six patients (49 male, 37 female, median age 47 years) were included. 38 patients suffered from low-grade and 48 from high-grade glioma. Median follow-up was 15 months after second treatment. Fifty-eight patients received upfront EBRT (median total dose: 60 Gy), and 28 upfront SBT (median reference dose: 54 Gy, median dose rate: 10.0 cGy/h). Median time interval between treatments was 19 months. RN was diagnosed in 8/75 patients. The 1- and 2-year risk of RN was 5.1% and 11.7%, respectively. Tumor volume and irradiation time of SBT, number of implanted seeds, and salvage EBRT were risk factors for RN. Neither of the BED values nor the time interval between both treatments gained prognostic influence. Conclusion The combination of upfront EBRT and salvage SBT or vice versa is feasible for glioma patients. The risk of RN is mainly determined by the treatment volume but not by the interval between therapies.

Sign in / Sign up

Export Citation Format

Share Document